Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / Common Stock, $0.001 par value
-
Shares outstanding
-
99,963,154
-
Total 13F shares
-
89,687,591
-
Share change
-
-369,273
-
Total reported value
-
$8,740,480,340
-
Put/Call ratio
-
30%
-
Price per share
-
$97.48
-
Number of holders
-
426
-
Value change
-
-$27,492,643
-
Number of buys
-
209
-
Number of sells
-
197
Institutional Holders of NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value (NBIX) as of Q2 2022
As of 30 Jun 2022,
NEUROCRINE BIOSCIENCES INC - Common Stock, $0.001 par value (NBIX) was held by
426 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
89,687,591 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, JANUS HENDERSON GROUP PLC, PRICE T ROWE ASSOCIATES INC /MD/, STATE STREET CORP, JPMORGAN CHASE & CO, Bellevue Group AG, DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C), Bank of New York Mellon Corp, and EATON VANCE MANAGEMENT.
This page lists
426
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.